Gabriel Contreras, MD
Nephrology · Miami, FLNPI 1891723383
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $129,525 of the $133,056 with a category attached, or 97.3%. 16 manufacturers reported payments, led by Genentech, Inc. at 42.4% of the total. Among nephrology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 88 payments — averaging $1512.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$56K
- GSK$24K
- Roche Products Limited$21K
- EMD Serono, Inc.$18K
- F. Hoffmann-la Roche AG$9K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$5K
- plus $545 from 10 others
Across 78 payments — averaging $2557.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Travere Therapeutics, Inc.$97K
- Genentech, Inc.$67K
- GSK$36K
What the payments were for
- Consulting fees$129,52597%
- Travel & lodging$1,8521%
- Food & beverage$1,6161%
- Education$630%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 23 | $56,432 |
| GSK | 32 | $23,719 |
| Roche Products Limited | 7 | $20,920 |
| EMD Serono, Inc. | 5 | $18,000 |
| F. Hoffmann-la Roche AG | 3 | $8,680 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $4,760 |
| Fresenius USA Marketing, Inc. | 6 | $109 |
| Bayer | 1 | $109 |
| OPKO Pharmaceuticals, LLC | 2 | $90 |
| Amgen | 1 | $84 |
| Baxter Healthcare | 2 | $44 |
| Akebia Therapeutics Inc | 1 | $25 |
| Recor Medical Inc | 1 | $24 |
| Cook Medical LLC | 1 | $24 |
| Ardelyx, Inc. | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$133,056 in reported general payments places this provider in the 95th percentile of 756 nephrology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 112 | $93,665 |
| JardianceEmpagliflozin | 41 | $35,317 |
| VeltassaPatiromer Calcium Sorbitex | 12 | $14,445 |
| Sevelamer Carbonate | 23 | $7,302 |
| ProsolParenteral Amino Acid 20% No.1 | 14 | $3,704 |
| Telmisartan | 116 | $3,652 |
| Telmisartan-AmlodipineTelmisartan/Amlodipine | 22 | $2,706 |
| Mycophenolate Mofetil | 45 | $2,688 |
| Tacrolimus | 34 | $2,344 |
| Amlodipine Besylate | 273 | $1,868 |
| Losartan Potassium | 160 | $1,297 |
| Valsartan | 48 | $1,099 |
| Rosuvastatin Calcium | 59 | $845 |
| Nebivolol Hcl | 11 | $845 |
| Olmesartan Medoxomil | 38 | $775 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Miami
- Alessia FornoniMiami$97K
- Jonathan da CostaMiami$74K
- Yelena DrexlerMiami$43K
- Jochen ReiserMiami$43K
- Alba Gonzalez-OchoaMiami$39K
- Jorge BusseMiami$28K
- Loay SalmanMiami$14K
- David RothMiami$12K
- Arvind MadanOrlando$943K
- John CopleyWeston$934K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.